#NTLA #c6a90f23-055d-40ba-af90-27e7b602a164 #investing #Health #Care

Origin | Interest | Match

Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026 Intellia Therapeutics (Nasdaq: NTLA) presented four posters at AAAAI 2026 on lonvoguran ziclumeran (lonvo-z; NTLA-2002) for hereditary angioedema (HAE). A pooled Phase 1/2 cohort (n=32) given a one-time 50 mg dose showed durable plasma kallikrein reductions and a mean monthly attack rate ≤0.2 through up to three years.Key readouts: 96% mean reduction in HAE attacks versus baseline, 31/32 (97%) attack-free and LTP-free at data cutoff, and 86% of 28 patients with >6 months follow-up attack-free and LTP-free for >6 months. A patient survey (n=100) highlighted ongoing treatment burden.

#NTLA Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026

www.stocktitan.net/news/NTLA/intellia-thera...

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM Intellia Therapeutics (Nasdaq: NTLA) announced the FDA has lifted the clinical hold on the IND for the MAGNITUDE Phase 3 trial of nexiguran ziclumeran (nex-z) in ATTR-CM, allowing enrollment to resume with enhanced safety measures.Holds were originally placed on October 29, 2025 after a patient experienced Grade 4 liver transaminase elevations and increased bilirubin. Mitigations include intensified liver monitoring, short-term steroid guidance, new exclusion criteria (including ejection fraction <25% and recent cardiovascular instability), and exclusion for certain liver abnormalities. MAGNITUDE plans ~1,200 patients (2:1 randomization, single 55 mg infusion); MAGNITUDE-2 enrolls ~60 ATTRv-PN patients (1:1).

#NTLA Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

www.stocktitan.net/news/NTLA/intellia-thera...

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027 Process underway to reactivate global sites for MAGNITUDE-2 Phase 3 clinical trial of nex-z in ATTRv-PN; enrollment completion expected in second

#NTLA Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

www.stocktitan.net/news/NTLA/intellia-thera...

#NTLA #b8b83e63-82c8-4cc9-b58b-f8f691f006b0 #investing #Health #Care

Origin | Interest | Match

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-up Consistent trend in disease stability or improvement in multiple measures of cardiomyopathy, regardless of NYHA Class, at 24 months compared to baseline Longer-term safety

#NTLA Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

www.stocktitan.net/news/NTLA/intellia-thera...

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Deep, stable and durable reductions in kallikrein observed Among 32 patients who received a 50 mg dose of lonvo-z as of data cutoff: 31 (97%) were attack-free and long-term prophylaxis (LTP)-free 24 (75%) were attack-free and LTP-free for at least seven months (up to 32 months) Among the 11

#NTLA Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

www.stocktitan.net/news/NTLA/intellia-thera...

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! Weekly Top Unu

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

Weekly Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #GSIT 84% OTM
2. #DGXX 68% OTM
3. #BYND 61% OTM
4. #CAPR 59% OTM
5. #NTLA 57% OTM

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#UUUU, #NTLA, #HIMS, #NUAI, #BIDU

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #UUUU 97% OTM
2. #NTLA 75% OTM
3. #HIMS 60% OTM
4. #IONQ 57% OTM
5. #MSTR 51% OTM

#OptionFlow #OptionsTrading #Trading

Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates Intellia Therapeutics (NASDAQ:NTLA) reported Q3 2025 results and clinical updates on November 6, 2025. The company said the FDA placed a clinical hold on the MAGNITUDE and MAGNITUDE-2 Phase 3 trials of nex-z after rare Grade 4 liver transaminase elevations; more than 650 patients are enrolled in MAGNITUDE and 47 patients in MAGNITUDE-2. Intellia completed enrollment in the Phase 3 HAELO trial of lonvo-z and expects topline HAELO data by mid-2026, with a potential U.S. launch in 1H 2027. Cash, cash equivalents and marketable securities were $669.9M at September 30, 2025, and are expected to fund operations into mid-2027. Third-quarter net loss was $101.3M.

#NTLA Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates

www.stocktitan.net/news/NTLA/intellia-thera...

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #OKLO 74% OTM
2. #HIMS 58% OTM
3. #NTLA 52% OTM
4. #CYBN 39% OTM
5. #BYND 38% OTM

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! AM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

AM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #OKLO 74% OTM
2. #NTLA 52% OTM
3. #BYND 44% OTM
4. #CYBN 39% OTM
5. #CIFR 32% OTM

#OptionFlow #OptionsTrading #Trading

Most Searched, Monday October 27, 2025 – Crystal Equity Research

Most searched small-cap stocks, Mon Oct 27th - #UAMY #LAC #OGN #JBLU #RR #LAES #ONDS #NTLA #RECT #GSIT #HIVE #DVLT #USAR #PPTA #INDP #CAAS #BYND #BORR #ASST #ALLO - More: crystalequityresearch.com/most-searche... - #smallcap

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) Intellia Therapeutics (NASDAQ:NTLA) announced a temporary pause of patient dosing and screening in its Phase 3 MAGNITUDE and MAGNITUDE-2 trials of nexiguran ziclumeran (nex-z) for ATTR-CM and ATTR-PN after an October 24, 2025 safety event.The event involved a patient dosed on September 30, 2025 who developed Grade 4 liver transaminase elevations and increased total bilirubin, met protocol pausing criteria, was hospitalized and is receiving care. The company said it is consulting experts and engaging regulators. As of October 27, 2025, >650 ATTR-CM patients are enrolled in MAGNITUDE, 47 patients in MAGNITUDE-2, and an estimated >450 patients have been dosed with nex-z. A conference call and webcast were scheduled for 8:30 a.m. ET the same day.

#NTLA Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

www.stocktitan.net/news/NTLA/intellia-thera...

#CRSP #VRTX #NTLA #VKTX #RXRX #5b579626-43df-4614-9f4c-db97b47a31e7 #investing

Origin | Interest | Match

#NTLA #8d15018b-d148-4763-b798-985c1d81039f #investing

Origin | Interest | Match

Just In: ( NASDAQ: #NTLA ) Cathie Wood Goes Shopping: 3 Rising Stocks She Just Bought

News; ( NASDAQ: #NTLA ) Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema Completed patient enrollment within nine months with nearly half enrolled from the U.S. Expect to report Phase 3 topline data in the first half of 2026 On track to submit BLA in the second half of 2026 for an anticipated U.S. launch in the first half of 2027 Plan to present additional data from the

#NTLA Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

www.stocktitan.net/news/NTLA/intellia-thera...

News; ( NASDAQ: #NTLA ) Why big players are pouring millions in THIS biotech stock

Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress Intellia Therapeutics (NASDAQ:NTLA) reported strong Q2 2025 results and significant progress in its clinical programs. The company ended Q2 with $630.5 million in cash, expecting to fund operations into H1 2027. Key highlights include accelerated enrollment in the Phase 3 MAGNITUDE trial for ATTR-CM, which will expand to approximately 1,200 patients, and the Phase 3 HAELO study for HAE completing randomization ahead of schedule.The company presented compelling three-year follow-up data for lonvo-z in HAE, showing a 98% reduction in monthly attack rates. For nex-z in ATTR amyloidosis, Phase 1 data demonstrated strong TTR reduction in both wild-type and variant ATTR-CM patients. The company strengthened its commercial readiness with key leadership appointments and remains on track for BLA submission for lonvo-z in H2 2026.

#NTLA Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress

www.stocktitan.net/news/NTLA/intellia-thera...

Leading CRISPR Pioneer Intellia Therapeutics Announces Q2 2025 Financial Results Date Gene editing pioneer Intellia to reveal latest CRISPR therapy progress and Q2 2025 financials. Join key biotech earnings call August 7. Get insights.

#NTLA Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

www.stocktitan.net/news/NTLA/intellia-thera...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks gapping down in trading, Thu May 29th - #TATT #HUSA #RAPP #NTLA #MULN #FNGR #EOSE #REVB #BROG #CAL - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress Intellia Therapeutics (NASDAQ:NTLA) reported its Q1 2025 financial results and clinical progress. The company is advancing three key Phase 3 trials: HAELO study for hereditary angioedema (HAE), MAGNITUDE-2 for hereditary ATTR amyloidosis with polyneuropathy, and MAGNITUDE for ATTR with cardiomyopathy. Financial highlights include a cash position of $707.1M expected to fund operations into H1 2027, though this represents a decrease from $861.7M in Q4 2024. Q1 revenue was $16.6M, down from $28.9M year-over-year, with a net loss of $114.3M. Clinical milestones include completing HAELO study enrollment in Q3 2025, presenting additional NTLA-2002 Phase 1 data at EAACI Congress in June, and sharing longer-term data for both ATTR-CM and ATTRv-PN patients in H2 2025. The company's lead programs utilize CRISPR-based gene editing technology delivered through lipid nanoparticles.

#NTLA Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

www.stocktitan.net/news/NTLA/intellia-thera...

Final Chance for NTLA Investors to Join Major Securities Fraud Case Against Intellia Therapeutics Intellia Therapeutics faces class action lawsuit over alleged securities fraud. Investors have until April 14, 2025, to join the case and seek compensation for losses.

Final Chance for NTLA Investors to Join Major Securities Fraud Case Against Intellia Therapeutics #United_States #Los_Angeles #Schall_Law_Firm #Intellia_Therapeutics #NTLA

NTLA calls for meaningful participation in reparation talks NTLA calls for meaningful participation in reparation talks NBC Online Thu, 04/10/2025 - 19:19

#Reparations #GenocideJustice #NTLA #NamaPeople #Ovaherero

Class Action Lawsuit Launched Against Intellia Therapeutics: Key Details for Investors A class action lawsuit has been filed against Intellia Therapeutics, urging investors to participate before the April 2025 deadline. Learn the crucial details.

Class Action Lawsuit Launched Against Intellia Therapeutics: Key Details for Investors #USA #New_York #Class_Action #Intellia_Therapeutics #NTLA